Diabetic Foot News and Research

RSS

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.

23 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

8 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

7 Feb 2011

SANUWAVE Health raises $4,102,660 from exercise of Options

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, announces that it has raised gross proceeds of $4,102,660 from the exercise of Options that were issued as part of the sale of Units to accredited investors during 2010. The Options had an expiration date of January 31, 2011.

7 Feb 2011

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

CardioVascular BioTherapeutics, Inc. today announced it has submitted an application to the U.S. FDA to obtain "fast track" designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient fibroblast growth factor-1 (FGF-1).

4 Feb 2011

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.

3 Feb 2011

KCI announces agreement to license Wright Medical Group's GRAFTJACKET for wound care

Kinetic Concepts, announced today an agreement to license Wright Medical Group, GRAFTJACKET brand for use in marketing the LifeCell™ acellular human dermal-based regenerative tissue matrix for wound applications such as diabetic foot ulcers and venous stasis ulcers.

31 Jan 2011

MGH investigators develop novel system to deliver growth factors to chronic wounds

Massachusetts General Hospital investigators have developed a novel system for delivery of growth factors to chronic wounds such as pressure sores and diabetic foot ulcers.

27 Jan 2011

Oxygen Biotherapeutics and SMP sign Binding Letter of Intent for joint chronic ischemic wound research

Oxygen Biotherapeutics, Inc. and privately held Sarasota Medical Products, Inc. (SMP) of Sarasota, FL, today announced they signed a Binding Letter of Intent to determine the feasibility of pursuing a joint research and development venture for treating chronic ischemic wounds. The venture will be based on combining Oxygen's Wundecyte™ PFC formulation with SMP's topical medical devices.

16 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

SANUWAVE third quarter revenues increase to $278,000

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and nine months ended September 30, 2010 and provided a business update.

12 Nov 2010

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

Nanotherapeutics, Inc. announced that it has been awarded a contract by the U.S. Department of Defense to support a clinical trial for treating dehisced surgical wounds with the Company's NanoDOX Hydrogel, a topical doxycycline hydrogel for chronic wounds.

4 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Majority of Americans with diabetic foot ulcer suffer from PAD

A new analysis published by THE SAGE GROUP, concludes that peripheral artery disease (PAD) afflicts 2.0-3.7 million U.S. citizens with diabetic foot ulcers (DFU). Approximately 1 million diabetic foot ulcer patients suffer from the most severe and deadly form of PAD, critical limb ischemia.

19 Oct 2010

Saudi FDA approves Apligraf for treatment of diabetic foot ulcers, chronic wounds

Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia. Apligraf is a living cell based product used by physicians to heal chronic wounds in patients in the U.S. and around the world.

29 Sep 2010

Patient follow-up complete in SANUWAVE's dermaPACE Phase III IDE trial for diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced the completion of patient follow-up in the Company's pivotal Phase III, Investigational Device Exemption (IDE) clinical trial with dermaPACE™ for the treatment of diabetic foot ulcers.

22 Sep 2010

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that patient screening in its DSC127 Phase 2 trial in diabetic foot ulcer healing will be completed tomorrow, and that enrollment in the trial will conclude on September 30. This randomized, double-blind, placebo controlled study of up to 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period, among other outcomes.

14 Sep 2010

Emunamedica licenses technology for near-infrared wound monitor from Drexel University

Patients with diabetes-associated wounds could receive faster and more effective treatment thanks to a non-invasive device that monitors wound healing and is one step closer to market. Emunamedica LLC, a Florida-based healthcare start-up, has licensed technology for a near-infrared wound monitor from Drexel University. The device was developed by Dr. Elisabeth Papazoglou and Dr. Leonid Zubkov of Drexel's School of Biomedical Engineering, Science and Health Systems in collaboration with Dr. Michael S. Weingarten, M.D. of Drexel College of Medicine and their teams.

19 Aug 2010

Podiatrist reduces leg amputation risk in diabetics: Study

People with diabetic foot problems can lower their risk of leg amputation by relying on coordinated care that includes a podiatrist, according to a recent study. For instance, those with diabetes-related foot ulcers can reduce their risk of amputation by 31 percent.

19 Aug 2010

Diabetic Foot News and Research

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

SANUWAVE Health raises $4,102,660 from exercise of Options

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

KCI announces agreement to license Wright Medical Group's GRAFTJACKET for wound care

MGH investigators develop novel system to deliver growth factors to chronic wounds

Oxygen Biotherapeutics and SMP sign Binding Letter of Intent for joint chronic ischemic wound research

Researchers synthesize wound-healing peptides

SANUWAVE third quarter revenues increase to $278,000

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Majority of Americans with diabetic foot ulcer suffer from PAD

Saudi FDA approves Apligraf for treatment of diabetic foot ulcers, chronic wounds

Patient follow-up complete in SANUWAVE's dermaPACE Phase III IDE trial for diabetic foot ulcers

Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end

Emunamedica licenses technology for near-infrared wound monitor from Drexel University

Podiatrist reduces leg amputation risk in diabetics: Study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News